MC lesions can persist for months or even years.
Burdazimer Gel 10.3% is positioned as a potential first-in-class novel topical treatment. Photo: Shutterstock.
Burdazimer Gel 10.3%, a nitric oxide-releasing topical, has shown benefit against molluscum contagiosum (MC), a skin infection for which there is currently no FDA-approved treatment.
MC is a viral infection of the skin that results in round, firm, painless bumps that vary in size and can be like the head of a pin or the eraser of a pencil and is caused by a member of the virus family. , Infections, common in children, can be acquired in a variety of ways.
With regard to medicine, according to the literature, nitric oxide modulates many physiological and molecular functions and is a therapeutic agent that has shown encouraging benefits for dermatological conditions. The gel combines burdazimer sodium gel with a hydrogel that promotes the release of nitrous oxide.
Precisely implied findings in a phase 3 randomized clinical trial that included a sample of 891 patients – with CM for more than six months – in patients treated with Berdazimer Gel versus Berdazimer Gel. completely removed. Those who used vehicle gel (active ingredient) (32.4% vs 19.7%). The study maintained that side effects were minimal and that mild to moderate erythema was the most commonly seen skin reaction.
Meaning bardazimer people 10.3% demonstrate favorable efficacy and safety in BC patients aged 6 months or more.
MC lesions can persist for months or years and affect approximately 6 million people annually in the United States, with the highest incidence occurring in children between the ages of 1 and 14. In patients with underlying atopic dermatitis, CM lesions may be more extensive, persistent, and prone to infection.
Burdazimer Gel 10.3% is positioned as a potential first-in-class novel topical treatment that when applied to the skin produces a controlled release of antiviral nitric oxide and probably inhibits viral replication of MC.
